ICI Pharmaceuticals' Diprivan (propofol)
On July 19, FDA, ICI reps and a member of the Anesthetic and Life Support Drugs Advisory Committee will hold a "mini-NDA Day" to discuss the supplemental NDA (No. 19-627) for Diprivan emulsion for intravenous injection for sedation during monitored anesthesia care. FDA originally had planned to review the supplement, which was filed in March 1990, at the committee's July 18 meeting; however, that meeting was cancelled because it was decided that a full committee discussion was unnecessary. Diprivan is currently marketed for induction and maintenance of anesthesia.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth